There were significant associations between OS of AML patients and age at diagnosis > 65 years (p < 0.001), WBC count ≥ 10,000 cells/mm3 (p = 0.025), LDH ≥ 600IU/L (p = 0.003), ECOG performance status grade ≥2 at diagnosis (p < 0.001), ELN high- and intermediate-risk (p < 0.001), and presence of FLT3 ITD mutation (p < 0.001), as we previously reported [30,31]. This evidence concerns the gene FLT3 and acute myeloid leukemia.